Immunity acquired from a Covid infection provides strong, lasting protection against the most severe outcomes of the illness, according to research published Thursday in The Lancet — protection, ...

It’s estimated around 3% of people in the UK experience long COVID – persistent, long-lasting symptoms after a COVID-19 infection. Long COVID encompasses a range of health problems that can begin ...

COVID-19 is a respiratory disease. Yet, from the earliest days of the pandemic, the cardiovascular risks associated with SARS-CoV-2 infection were clear: individuals with severe cases of COVID-19 ...

Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential efficacy ...

The National Academies said the condition could involve up to 200 symptoms, make it difficult for people to work and last for months or years. By Pam Belluck One of the nation’s premier medical ...

Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk for ...